Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - atorvastatina calcica trihidrato - comprimido recubierto con pelÍcula - 10 mg - atorvastatina calcica trihidrato 10 mg - atorvastatina

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - atorvastatina calcica trihidrato - comprimido recubierto con pelÍcula - 40 mg - atorvastatina calcica trihidrato 40 mg - atorvastatina

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - atorvastatina calcica trihidrato - comprimido recubierto con pelÍcula - 80 mg - atorvastatina calcica trihidrato 80 mg - atorvastatina

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - atorvastatina calcica trihidrato - comprimido recubierto con pelÍcula - 20 mg - atorvastatina calcica trihidrato 20 mg - atorvastatina

Portugāle - portugāļu - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - raloxifeno - comprimido revestido por película - 60 mg - raloxifeno, cloridrato 60 mg - raloxifene - genérico - duração do tratamento: longa duração

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

baxter oncology gmbh - ciclofosfamida - comprimido recubierto - 50 mg - ciclofosfamida 50 mg - ciclofosfamida

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

marion merrell s.a. - rifampicina; isoniazida; pirazinamida - comprimido recubierto - 120 mg/50 mg/300 mg - rifampicina 120 mg; isoniazida 50 mg; pirazinamida 300 mg - rifampicina, pirazinamida e isoniazida

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

eli lilly and company - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-y

Spānija - spāņu - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - fluvoxamina maleato - comprimido recubierto con pelÍcula - 50 mg - fluvoxamina maleato 50 mg - fluvoxamina